U.S. fintech Synapse expands in Brazil, looks to Latam, India- CEO




  • In US
  • 2022-09-29 17:40:49Z
  • By Reuters

By Tatiana Bautzer

SAO PAULO (Reuters) - U.S. fintech Synapse is close to reaching 1 million accounts held by Brazilians and is planning expansion to other countries in Latin America and India, CEO Sakaet Pathak said.

Synapse provides U.S.-based checking accounts to clients abroad and has about 13 million users. Clients open the accounts through Synapse partners in their home countries. Earlier this week, Synapse announced such a partnership with Brazilian fintech Nomad and already provides U.S accounts to clients of Banco Inter SA.

Most Brazilians use these accounts to pay for expenses during trips or to invest in U.S. financial markets. Pathak said the company is in talks for new partnerships to offer the accounts to customers in Asia, mainly in India, and in other Latin American countries such as Mexico and Argentina.

Transferring assets from volatile local currencies to dollar investments is one of the main reasons for clients to open U.S. accounts, Pathak said in a video interview. Synapse owns a U.S. brokerage and other banking products are provided by the company's partners. The accounts are covered by FDIC deposit insurance.

Synapse had its last funding round in 2019, when it raised $30 million with venture capital firm Andreessen Horowitz, and it expects to reach break even this year, the CEO said. The company does not plan to raise more capital in the short term.

(Reporting by Tatiana Bautzer; Editing by Cynthia Osterman)

COMMENTS

More Related News

Price hikes for some Medicare therapies unsupported by clinical benefits data - Report
Price hikes for some Medicare therapies unsupported by clinical benefits data - Report

The three costliest therapies under Medicare health insurance in the United States saw price hikes in 2020 but there was not enough evidence of new clinical benefits, the Institute for Clinical and Economic Review (ICER) said on Tuesday. Horizon Therapeutics' gout treatment Krystexxa's list price increased by 12%, which led to an additional out-of-pocket expense of $3,210 per patient being spent on average. The ICER, a group that reviews the value of medicines, said drugmakers hiked prices on seven of the 10 costliest prescription drugs in 2021 too, without enough clinical evidence justifying the hike.

Aluminum plants in the U.S. are releasing tons of a highly potent greenhouse gas, unlike their counterparts abroad
Aluminum plants in the U.S. are releasing tons of a highly potent greenhouse gas, unlike their counterparts abroad

A Century Aluminum plant in Kentucky vented tons of perfluorocarbons, or PFCs, which are among the most potent and longest-lasting greenhouse gases on the...

China says U.S. nuclear weapons report is speculation
China says U.S. nuclear weapons report is speculation
  • US
  • 2022-12-06 04:57:00Z

China's defence ministry on Tuesday dismissed a Pentagon report about the pace of its nuclear weapons programme as unfair "gesticulation" and speculation...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: US